Phase I trial of EyeGate's non-invasive ocular drug delivery system launched
A Phase I study testing safety and tolerability of a new non-invasive drug delivery system, the EyeGate II Ocular Drug Delivery System (EyeGate Pharma), has been launched.
A Phase I study testing safety and tolerability of a new non-invasive drug delivery system, the EyeGate II Ocular Drug Delivery System (EyeGate Pharma), has been launched. The new system is designed to treat serious ocular disease of both the front and the back of the eye, and uses a range of iontophoretic dose levels with a citrate buffer.
EyeGate Pharma has enrolled 95 healthy adult volunteers in the single centre, randomized, single masked, comparative group study, which is designed to establish the maximum tolerated current that can be employed during iontophoretic treatment with the EyeGate II Delivery System. An earlier study, assessing safety, tolerability and efficacy, enrolled 89 patients with severe ocular inflammation and demonstrated good patient tolerance, a decrease in inflammatory markers and an increase in visual acuity.
Two separate Phase II trials, for severe uveitis and dry eye, are planned for later this year.
AAO 2024: Transient vision loss with Alexander Fein, MD
October 21st 2024Alexander Fein, MD, spoke with the Eye Care Network to share how to approach a patient presenting with transient vision loss, what this type of vision loss can mean, and what additional testing might be needed to determine the best plan for care.
AAO 2024: Optimal pupil size reduction percentage for near vision improvement in presbyopia
October 21st 2024Jennifer Loh, MD, shared insights from on her presentation at the American Academy of Ophthalmology meeting in Chicago on the effects of CSF-1, which is the lowest effective concentration of pilocarpine approved in the United States.
